Amgen Inc. (AMGN) Amgen this week said it submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its denosumab drug to combat bone destruction in cancer patients. The BLA submission summarizes clinical experience from head-to-head trials versus Zometa, or zoledronic acid. Denosumab is meant to target cancer induced bone destruction, or bone metastases. [...]